Phase 2 study of veliparib plus FOLFIRI ± bevacizumab versus placebo plus FOLFIRI ± bevacizumab in metastatic colorectal cancer.

Vera Gorbunova,Thaddeus Beck,Ralf Hofheinz,Pilar García-Alfonso,Marina Nechaeva,Antonio Cubillo Gracian,László Mangel,Elena Elez,Dustin A. Deming,Ramesh K. Ramanathan,Alison Torres,Danielle Marie Sullivan,Philip Komarnitsky,Jordan Berlin

Phase 2 study of veliparib plus FOLFIRI ± bevacizumab versus placebo plus FOLFIRI ± bevacizumab in metastatic colorectal cancer.

2018

Vera Gorbunova
Thaddeus Beck
Ralf Hofheinz
Pilar García-Alfonso
Marina Nechaeva
Antonio Cubillo Gracian
László Mangel
Elena Elez
Dustin A. Deming
Ramesh K. Ramanathan
Alison Torres
Danielle Marie Sullivan
Philip Komarnitsky
Jordan Berlin

3543Background: Survival rates for patients with metastatic colorectal cancer (mCRC) are low. Current front-line therapy includes a combination of irinotecan/5-fluorouracil/leucovorin (FOLFIRI) ± b...

Keywords:

Bevacizumab
FOLFIRI
Veliparib
Placebo
Phases of clinical research
Cancer research
Colorectal cancer
Physical therapy
Medicine
Fluorouracil
Irinotecan
Oncology
Internal medicine
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations